In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Optimal timing for cardiovascular magnetic resonance after ST-segment elevation myocardial infarction for effective risk stratification

Session Moderated ePosters session 2: frontiers in viability imaging

Speaker Anna Giulia Pavon

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Late Gadolinium Enhancement and Viability
  • Session type : Moderated Posters
  • FP Number : 46

Authors : A G Pavon (Lausanne,CH), G Pontone (Milan,IT), R Symons (Leuven,BE), M Francone (Rome,IT), J Zalewski (Krakow,PL), A Barison (Pisa,IT), GD Aquaro (Pisa,IT), G Muscogiuri (Milan,IT), O Muller (Lausanne,CH), A Baggiano (Leuven,BE), D Andreini (Milan,IT), PG Camici (Milan,IT), J Schwitter (Lausanne,CH), J Bogaert (Leuven,BE), PG Masci (Lausanne,CH)

Authors:
A G Pavon1 , G Pontone2 , R Symons3 , M Francone4 , J Zalewski5 , A Barison6 , GD Aquaro6 , G Muscogiuri2 , O Muller7 , A Baggiano3 , D Andreini2 , PG Camici8 , J Schwitter1 , J Bogaert3 , PG Masci1 , 1University Hospital Centre Vaudois (CHUV), Centre of Cardiac Magnetic Resonance - Lausanne - Switzerland , 2Cardiology Center Monzino IRCCS - Milan - Italy , 3Gasthuisberg University Hospital - Leuven - Belgium , 4Sapienza University of Rome - Rome - Italy , 5John Paul II Hospital - Krakow - Poland , 6Fondazione Toscana Gabriele Monasterio - Pisa - Italy , 7University Hospital Centre Vaudois (CHUV) - Lausanne - Switzerland , 8San Raffaele Hospital, Department of Cardiology - Milan - Italy ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii14

Background: In ST-segment-elevation myocardial infarction (STEMI), cardiovascular magnetic resonance (CMR) holds the potentiality to improve risk stratification beyond Thrombolysis-in-Myocardial-Infarction (TIMI) risk-score. Nevertheless, the optimal timing for CMR after STEMI remains poorly defined. Objectives: Comparing prognostic performance of three different stratification strategies according to the timing of CMR after STEMI. Methods: The population of this prospective registry-based study included 511 reperfused STEMI patients. All patients underwent post-reperfusion (median:4-days post-STEMI) and follow-up (median:4.8-months post-STEMI) CMR. Left ventricular (LV) volumes, function, infarct-size and microvascular-obstruction extent (MVO) were quantified. Primary end-point was a composite of all-death and heart failure (HF) hospitalization.Three multivariate models were developed including TIMI risk-score plus early post-STEMI (early-CMR) or follow-up CMR (deferred-CMR) or both CMRs parameters along with adverse LV remodeling (paired-CMRs). Results: During a median follow-up of 8.5 years, primary end-point occurred in 85 patients (23 deaths; 38 HF hospitalization). Early-CMR, deferred-CMR and paired-CMRs demonstrated similar predictive value for primary end-point (C-statistic: 0.726, 0.728, 0.738, respectively; P=0.663). However, early-CMR enabled to correctly estimate poor outcome in 4 of 7 patients (56%) developing primary end-point between early- and deferred-CMR. Conclusions: In STEMI, early-CMR should be considered the preferred strategy for timely effective risk stratification.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are